Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Maintains Target Price $393
Jefferies Sticks to Their Buy Rating for West Pharmaceutical Services (WST)
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating
Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $393
Stephens Adjusts Price Target on West Pharmaceutical Services to $380 From $340
Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)
DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating
DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and HCA Healthcare (HCA)
Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Cuts Target Price to $345
Stephens Adjusts Price Target on West Pharmaceutical Services to $340 From $400
Hold Rating on West Pharmaceutical Services Amid Forecast Challenges and Demand Slowdown
Stephens Adjusts Price Target on West Pharmaceutical Services to $400 From $420
Jefferies Adjusts Price Target on West Pharmaceutical Services to $426 From $423
West Pharmaceutical Services: Strong Q1 Performance and Upbeat FY24 Outlook Bolster Buy Rating
Buy Rating Affirmed for West Pharmaceutical Services on Robust Market Position and Growth Prospects
West Pharmaceutical Servs Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Ultragenyx Pharmaceutical (RARE) and West Pharmaceutical Services (WST)
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $470
West Pharmaceutical Servs Analyst Ratings